TO-O-1001 & TO-O-1002 won the 2023 R&D 100 Award
MG-O-1002 (TO-O-1002) project won the 2023 Edison AwardsTM
ITRI Special Issue ----
Interview with Dr. Sean Chen, chairman of TheratOcular Biotek
New blue ocean for ophthalmology drugs; Taiwanese manufacturers are actively improving innovative technologies
Old formula New amazing effect, TheratOcular Biotek makes it easy to treat eye diseases - Executive VP Simon Huang Interview
63th Annual Meeting of Ophthalmology & 15th Asia Pacific Vitreoretinal Society (APVRS) Congress
Press conference of innovative eye drops
TO-O-1002 Investigator meeting (IM) in Thailand
The phase II clinical trial of TO-O-1002 approved by the Central Research Ethics Committee (CREC) in Thailand on 11 Aug 2022.
The phase I/II clinical trials of TO-O-1001 approved by the Australian Human Research Ethics Committee (HREC) on 4 Aug 2022.
The company Chair, Dr. Sean Chen, and the SAB Chair, Dr. Lu Da-Wen, get together with all the honorary members of the Company Scientific Advisory Board (SAB) in a banquet.
TheratOcular Team meet up with its RD/BD partner, the ITRI-BEL team, at the 2022 Asia Biotech Exhibition.